Speakers envision custom therapies that merge MIGS devices with extended-release drugs.
The government plans to scrutinize devices based on the risk they pose.
The surgeon also talked about his transition to chief medical officer.
A major restructuring of Alcon remains a work in progress, while competitive pressures weigh on the division's cataract and refractive segments.
The lens gained CE marking in November 2016.
Novartis paid $375 million up front, plus $90 million in early milestone payments, for presbyopia technology.
Company told analysts it is no longer pursuing its PDGF program after clinical trial failure in 2016.
Dry eye market has expanded 30 percent since mid-2016, CCO says.
Glenn Sblendorio has moved into the role following the departure of company co-founder Samir Patel, MD.
Abbott Medical Optics reported a 7.7 percent increase in revenues for Q4-2017, while Carl Zeiss Meditec saw quarterly revenues grow 6.6 percent.
TearScience’s LipiFlow procedure has seen marked growth in the last year.
The technology is designed to enhance the topical bioavailability, stability, and safety of traditionally insoluble or unstable drugs.
Leading manufacturers have been addressing disadvantages and improving other characteristics of the material.
AGTC and Bionic Sight will collaborate on an optogenetic treatment to restore retinal function; and Pixium Vision announces that 10 patients have been implanted with the Iris II retinal prosthesis.
Retinal disease is the largest ophthalmic segment in the country due to the role of anti-VEGFs in treatment.
The US market will represent nearly a third of global revenues, as older units are replaced and prices rise.
France-based firm plans to file an IND application for its nitric oxide-donating bimatoprost analog in Q4-2017.
Financial details of the deal were not disclosed.
Honorees are chosen by more than 30 thousand ophthalmologists around the world.
You are not currently logged in.
©2017 Market Scope
Lost your Password